Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daisy Chou

Vascular Surgery Fort Worth, TX Medical Doctor

NPI 1891037628 CMS profile 815593

1500 S Main St Fl 2, Suite 110, Fort Worth, TX 76104

Open in the dashboard

General payments

$11,388

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daisy Chou of Fort Worth, TX is reported in the CMS Open Payments database as having received $11,388 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $653 25
2024 General $792 23
2023 General $864 27
2022 General $1,030 18
2021 General $1,550 13
2020 General $318 6
2019 General $6,181 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daisy Chou
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Daisy Chou were reported at $653. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Daisy Chou Vascular Surgery median Middle half National median
2019 $6,181 $796 $226–$2,363 $163
2020 $318 $348 $118–$1,110 $114
2021 $1,550 $471 $158–$1,421 $132
2022 $1,030 $725 $222–$2,183 $149
2023 $864 $836 $257–$2,440 $160
2024 $792 $909 $252–$2,619 $164
2025 $653 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $5,061 4 payments
  2. Silk Road Medical, Inc. $1,633 24 payments
  3. Inari Medical, Inc. $1,023 4 payments
  4. W. L. Gore & Associates, Inc. $966 9 payments
  5. Medtronic, Inc. $539 16 payments
  6. Endologix, Inc. $433 2 payments
  7. Boston Scientific Corporation $204 10 payments
  8. Bolton Medical Inc $197 3 payments
  9. Koya Medical, Inc. $186 7 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $165 7 payments
  11. Other $982 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,641 117 payments
  2. Grant $5,000 1 payment
  3. Travel and Lodging $659 4 payments
  4. Education $88 2 payments
Products named General payments · program years 2019–2025
  1. Endurant $5,000 1 payment
  2. FLOWTRIEVER CATHETER, S $1,984 6 payments
  3. ENROUTE 0.014 Guidewire $980 9 payments
  4. ENROUTE Transcarotid Stent System $980 9 payments
  5. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $980 9 payments
  6. ENHANCE Transcarotid Peripheral Access Kit $980 9 payments
  7. ENROUTE Transcarotid Stent $653 15 payments
  8. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $653 15 payments
  9. Alto Abdominal Stent Graft System $433 2 payments
  10. EXCLUDER AAA Endoprosthesis $245 2 payments
  11. Other $4,271 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$81,472

Medicare's payments for the services billed

Medicare patients

183

Average age 73

Services billed

560

99 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 49%
Arthritis 48%
Diabetes 46%
Chronic kidney disease 44%
Heart failure 34%
Atrial fibrillation 32%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $54
$54 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record